RESULTS	QOL was assessed in 3010 patients receiving either valsartan ( 160 mg twice daily ) or placebo in addition to prescribed background therapy ( beta-blockers or angiotensin-converting enzyme inhibitors ) , using the Minnesota Living with Heart Failure ( MLWHF ) questionnaire .\